Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome

Aswin Abraham, Anna Krasnodembskaya, Aswin Abraham, Anna Krasnodembskaya

Abstract

Acute respiratory distress syndrome (ARDS) is a serious and potentially fatal acute inflammatory lung condition which currently has no specific treatments targeting its pathophysiology. However, mesenchymal stem cells have been shown to have very promising therapeutic potential, and recently, it has been established that their effect is largely due to the transfer of extracellular vesicles (EVs). EVs have been shown to transfer a variety of substances such as mRNA, miRNA, and even organelles such as mitochondria in order to ameliorate ARDS in preclinical models. In addition, the fact that they have been proven to have the same effect as their parent cells combined with their numerous advantages over whole cell administration means that they are a promising candidate for clinical application that merits further research.

Keywords: cellular therapy; clinical translation; mesenchymal stem cells (MSCs); respiratory tract.

Conflict of interest statement

The authors declared no potential conflict of interest.

© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Figures

Figure 1
Figure 1
Transfer of miRNA, mRNA, and mitochondria from mesenchymal stem cells (MSCs) to different target cells by extracellular vesicles (EVs)

References

    1. Ashbaugh D, Bigelow DB, Petty T, Levine B. Acute respiratory distress in adults. Lancet. 1967;290:319‐323.
    1. Force AD, Ranieri VM, Rubenfeld GD. Acute respiratory distress syndrome. JAMA. 2012;307:2526‐2533.
    1. Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA. 2018;319:698‐710.
    1. Máca J, Jor O, Holub M, et al. Past and present ARDS mortality rates: a systematic review. Respir Care. 2017;62:113‐122.
    1. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293‐1304.
    1. Rawal G, Yadav S, Kumar R. Acute respiratory distress syndrome: an update and review. J Trans Intern Med. 2018;6:74‐77.
    1. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147‐163.
    1. Griffiths MJ, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6:e000420.
    1. Reilly JP, Calfee CS, Christie JD. Acute respiratory distress syndrome phenotypes. Semin Respir Crit Care Med. 2019;40:019‐030.
    1. Calfee CS, Delucchi K, Parsons PE, et al. Latent class analysis of ARDS subphenotypes: analysis of data from two randomized controlled trials. Lancet Respir Med. 2014;2:611‐620.
    1. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network . Higher versus lower positive end‐expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327‐336.
    1. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network . Comparison of two fluid‐management strategies in acute lung injury. N Engl J Med. 2006;354:2564‐2575.
    1. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195:331‐338.
    1. McAuley DF, Laffey JG, O'kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695‐1703.
    1. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691‐698.
    1. Johnson CL, Soeder Y, Dahlke MH. Concise review: mesenchymal stromal cell‐based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Translational Medicine. 2017;6:1141‐1151.
    1. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL‐37. Stem Cells. 2010;28:2229‐2238.
    1. Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67:533‐539.
    1. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187:751‐760.
    1. Curley GF, Ansari B, Hayes M, et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator‐induced lung injury. Anesthesiology. 2013;118:924‐932.
    1. Hall SR, Tsoyi K, Ith B, et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase‐1: the importance of neutrophils. Stem Cells. 2013;31:397‐407.
    1. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram‐negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302:L1003‐L1013.
    1. Jackson MV, Morrison TJ, Doherty DF, et al. Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells. 2016;34:2210‐2223.
    1. Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med. 2017;196:1275‐1286.
    1. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin‐induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA. 2009;106:16357‐16362.
    1. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med. 2014;2:1016‐1026.
    1. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24‐32.
    1. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154‐162.
    1. Bellingan G, Jacono F, Bannard‐Smith J, et al. Primary analysis of a phase 1/2 study to assess MultiStem® cell therapy, a regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST‐ARDS). B14. Late Break Clin Trials. 2019;199:A7353 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7353.
    1. Weiss AR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019;10:1191.
    1. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells. Front Immunol. 2014;5:148.
    1. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T‐cell responses by indoleamine 2,3‐dioxygenase‐mediated tryptophan degradation. Blood. 2004;103:4619‐4621.
    1. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E 2–dependent reprogramming of host macrophages to increase their interleukin‐10 production. Nat Med. 2009;15:42‐49.
    1. Witwer KW, Van Balkom BW, Bruno S, et al. Defining mesenchymal stromal cell (MSC)‐derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8:1609206.
    1. Yang L, Zhang Y, Cheng L, et al. Mesenchymal stem cells engineered to secrete pigment epithelium‐derived factor inhibit tumor metastasis and the formation of malignant ascites in a murine colorectal peritoneal carcinomatosis model. Hum Gene Ther. 2016;27:267‐277.
    1. Cai C, Hou L, Zhang J, et al. The inhibitory effect of mesenchymal stem cells with rAd‐NK4 on liver cancer. Appl Biochem Biotechnol. 2017;183:444‐459.
    1. Lee HY, Hong IS. Double‐edged sword of mesenchymal stem cells: cancer‐promoting versus therapeutic potential. Cancer Sci. 2017;108:1939‐1946.
    1. Romieu‐Mourez R, François M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN‐γ, TGF‐β, and cell density. J Immunol. 2007;179:1549‐1558.
    1. Chan JL, Tang KC, Patel AP, et al. Antigen‐presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon‐γ. Blood. 2006;107:4817‐4824.
    1. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I–and class II–mismatched recipient mice. Blood. 2005;106:4057‐4065.
    1. Ock SA, Rho GJ. Effect of dimethyl sulfoxide (DMSO) on cryopreservation of porcine mesenchymal stem cells (pMSCs). Cell Transplant. 2011;20:1231‐1239.
    1. Siekevitz P. Biological membranes: the dynamics of their organization. Annu Rev Physiol. 1972;34:117‐140.
    1. Van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213‐228.
    1. Ratajczak J, Wysoczynski M, Hayek F, Janowska‐Wieczorek A, Ratajczak MZ. Membrane‐derived microvesicles: important and underappreciated mediators of cell‐to‐cell communication. Leukemia. 2006;20:1487‐1495.
    1. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43‐51.
    1. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006;66:4795‐4801.
    1. Monsel A, Zhu YG, Gudapati V, Lim H, Lee JW. Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther. 2016;16:859‐871.
    1. Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
    1. Gardiner C, Vizio DD, Sahoo S, et al. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016;5:32945.
    1. Momen‐Heravi F. Isolation of extracellular vesicles by ultracentrifugation Extracellular Vesicles. New York, NY: Humana Press; 2017:25‐32.
    1. Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of extracellular vesicles: general methodologies and latest trends. Biomed Res Int. 2018;2018:1‐27.
    1. Cvjetkovic A, Lötvall J, Lässer C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J Extracell Vesicles. 2014;3:23111.
    1. Momen‐Heravi F, Balaj L, Alian S, et al. Current methods for the isolation of extracellular vesicles. Biol Chem. 2013;394:1253‐1262.
    1. Van Deun J, Mestdagh P, Sormunen R, et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles. 2014;3:24858.
    1. Benedikter BJ, Bouwman FG, Vajen T, et al. Ultrafiltration combined with size exclusion chromatography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies. Sci Rep. 2017;7:15297.
    1. Ludwig AK, De Miroschedji K, Doeppner TR, et al. Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales. J Extracell Vesicles. 2018;7:1528109.
    1. Kordelas L, Rebmann V, Ludwig AK, et al. MSC‐derived exosomes: a novel tool to treat therapy‐refractory graft‐versus‐host disease. Leukemia. 2014;28:970‐973.
    1. Salih M, Zietse R, Hoorn EJ. Urinary extracellular vesicles and the kidney: biomarkers and beyond. Am J Physiol Renal Physiol. 2014;306:F1251‐F1259.
    1. Nordin JZ, Lee Y, Vader P, et al. Ultrafiltration with size‐exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine. 2015;11:879‐883.
    1. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.
    1. Hartjes TA, Mytnyk S, Jenster GW, van Steijn V, van Royen ME. Extracellular vesicle quantification and characterization: common methods and emerging approaches. Bioengineering. 2019;6:7.
    1. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem Rev. 2018;118:1917‐1950.
    1. Barry OP, Praticò D, Savani RC, FitzGerald AG. Modulation of monocyte‐endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136‐144.
    1. Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase‐1. PLoS One. 2009;4:e7140.
    1. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell‐derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20:847‐856.
    1. Phinney DG, Di Giuseppe M, Njah J, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015;6:8472.
    1. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360:219‐223.
    1. Carré JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med. 2010;182:745‐751.
    1. Agrawal A, Mabalirajan U. Rejuvenating cellular respiration for optimizing respiratory function: targeting mitochondria. Am J Physiol Lung Cell Mol Physiol. 2015;310:L103‐L113.
    1. Gangadaran P, Rajendran RL, Lee HW, et al. Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia. J Control Release. 2017;264:112‐126.
    1. Wiklander OP, Brennan MÁ, Lötvall J, Breakefield XO, Andaloussi SE. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019;11:eaav8521.
    1. Murray LM, Krasnodembskaya AD. Concise review: intercellular communication via organelle transfer in the biology and therapeutic applications of stem cells. Stem Cells. 2019;37:14‐25.
    1. Weiss DJ, English K, Krasnodembskaya A, Isaza‐Correa JM, Hawthorne IJ, Mahon BP. The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Front Immunol. 2019;10:1228.
    1. Nassar W, El‐Ansary M, Sabry D, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016;20:21.
    1. Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin‐induced acute lung injury in mice. Stem Cells. 2014;32:116‐125.
    1. Fergie N, Todd N, McClements L, McAuley D, O'Kane C, Krasnodembskaya A. Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair. FASEB J. 2019;33:5585‐5598.
    1. Tang XD, Shi L, Monsel A, et al. Mesenchymal stem cell microvesicles attenuate acute lung injury in mice partly mediated by Ang‐1 mRNA. Stem Cells. 2017;35:1849‐1859.
    1. Monsel A, Zhu YG, Gennai S, et al. Therapeutic effects of human mesenchymal stem cell–derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med. 2015;192:324‐336.
    1. Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell‐derived extracellular vesicles attenuate influenza virus‐induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9:17.
    1. Gennai S, Monsel A, Hao Q, Park J, Matthay MA, Lee JW. Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Transplant. 2015;15:2404‐2412.
    1. McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014;306:L809‐L815.
    1. Park J, Kim S, Lim H, et al. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia. Thorax. 2019;74:43‐50.
    1. Hu S, Park J, Liu A, et al. Mesenchymal stem cell microvesicles restore protein permeability across primary cultures of injured human lung microvascular endothelial cells. Stem Cells Translational Medicine. 2018;7:615‐624.
    1. Varkouhi AK, Jerkic M, Ormesher L, et al. Extracellular vesicles from interferon‐γ–primed human umbilical cord mesenchymal stromal cells reduce Escherichia coli–induced acute lung injury in rats. Anesthesiology. 2019;130:778‐790.
    1. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294‐1301.
    1. Cao Y, Lyu YI, Tang J, Li Y. MicroRNAs: novel regulatory molecules in acute lung injury/acute respiratory distress syndrome. Biomed Rep. 2016;4:523‐527.
    1. Xie N, Liu G. ncRNA‐regulated immune response and its role in inflammatory lung diseases. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1076‐L1087.
    1. Zhu Z, Liang L, Zhang R, et al. Whole blood microRNA markers are associated with acute respiratory distress syndrome. Intensive Care Med Exp. 2017;5:38.
    1. Wei Li J, Wei L, Han Z, Chen Z. Mesenchymal stromal cells‐derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti‐apoptotic miR‐21‐5p. Eur J Pharmacol. 2019;852:68‐76.
    1. Yi X, Wei X, Lv H, et al. Exosomes derived from microRNA‐30b‐3p‐overexpressing mesenchymal stem cells protect against lipopolysaccharide‐induced acute lung injury by inhibiting SAA3. Exp Cell Res. 2019;383:111454.
    1. Song Y, Dou H, Li X, et al. Exosomal miR‐146a contributes to the enhanced therapeutic efficacy of interleukin‐1β‐primed mesenchymal stem cells against sepsis. Stem Cells. 2017;35:1208‐1221.
    1. Chen TS, Arslan F, Yin Y, et al. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC‐derived MSCs. J Transl Med. 2011;9:47.
    1. Pachler K, Lener T, Streif D, et al. A good manufacturing practice–grade standard protocol for exclusively human mesenchymal stromal cell–derived extracellular vesicles. Cytotherapy. 2017;19:458‐472.
    1. Mendt M, Kamerkar S, Sugimoto H, et al. Generation and testing of clinical‐grade exosomes for pancreatic cancer. JCI Insight. 2018;3:99263.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit